| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colorectal Neoplasms | 122 | 2022 | 561 | 10.570 |
Why?
|
| Genetic Predisposition to Disease | 68 | 2022 | 786 | 5.050 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 31 | 2020 | 36 | 3.490 |
Why?
|
| Polymorphism, Single Nucleotide | 54 | 2022 | 627 | 3.390 |
Why?
|
| Adenoma | 29 | 2013 | 132 | 3.120 |
Why?
|
| Folic Acid | 19 | 2019 | 123 | 2.770 |
Why?
|
| Breast Neoplasms | 43 | 2019 | 1536 | 2.300 |
Why?
|
| DNA Mismatch Repair | 31 | 2020 | 42 | 2.290 |
Why?
|
| Registries | 54 | 2019 | 733 | 2.140 |
Why?
|
| Mutation | 45 | 2019 | 1213 | 2.120 |
Why?
|
| Germ-Line Mutation | 22 | 2019 | 43 | 2.020 |
Why?
|
| Genome-Wide Association Study | 32 | 2022 | 240 | 1.940 |
Why?
|
| Microsatellite Instability | 26 | 2015 | 39 | 1.860 |
Why?
|
| Case-Control Studies | 70 | 2021 | 1553 | 1.770 |
Why?
|
| Risk Factors | 106 | 2021 | 5731 | 1.750 |
Why?
|
| Neoplasms, Second Primary | 19 | 2019 | 62 | 1.640 |
Why?
|
| Colonic Neoplasms | 17 | 2021 | 299 | 1.540 |
Why?
|
| DNA-Binding Proteins | 30 | 2019 | 700 | 1.500 |
Why?
|
| Middle Aged | 164 | 2021 | 21147 | 1.450 |
Why?
|
| Genetic Variation | 11 | 2019 | 220 | 1.430 |
Why?
|
| Aged | 117 | 2021 | 14862 | 1.280 |
Why?
|
| Female | 185 | 2021 | 38074 | 1.270 |
Why?
|
| Genotype | 37 | 2021 | 786 | 1.220 |
Why?
|
| DNA Methylation | 14 | 2017 | 193 | 1.210 |
Why?
|
| Genes, BRCA1 | 10 | 2013 | 47 | 1.200 |
Why?
|
| Adaptor Proteins, Signal Transducing | 20 | 2015 | 214 | 1.170 |
Why?
|
| Nuclear Proteins | 20 | 2017 | 271 | 1.140 |
Why?
|
| MutS Homolog 2 Protein | 21 | 2019 | 26 | 1.100 |
Why?
|
| Neoplasms | 15 | 2022 | 1667 | 1.100 |
Why?
|
| Humans | 214 | 2022 | 68618 | 1.090 |
Why?
|
| Heterozygote | 25 | 2020 | 174 | 1.090 |
Why?
|
| Genes, BRCA2 | 10 | 2013 | 35 | 1.090 |
Why?
|
| MutL Protein Homolog 1 | 26 | 2020 | 32 | 1.070 |
Why?
|
| Carcinoma | 5 | 2020 | 215 | 1.030 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 5 | 2013 | 12 | 0.980 |
Why?
|
| DNA Repair Enzymes | 17 | 2019 | 53 | 0.980 |
Why?
|
| DNA Repair | 9 | 2021 | 127 | 0.970 |
Why?
|
| Male | 130 | 2021 | 37321 | 0.950 |
Why?
|
| Aspirin | 16 | 2019 | 295 | 0.940 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 17 | 2020 | 20 | 0.900 |
Why?
|
| Adult | 103 | 2021 | 21403 | 0.900 |
Why?
|
| Endometrial Neoplasms | 9 | 2015 | 69 | 0.870 |
Why?
|
| CpG Islands | 10 | 2015 | 51 | 0.790 |
Why?
|
| Rectal Neoplasms | 6 | 2021 | 75 | 0.780 |
Why?
|
| DNA Glycosylases | 8 | 2016 | 21 | 0.760 |
Why?
|
| Smoking | 16 | 2016 | 1452 | 0.730 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 11 | 2020 | 240 | 0.720 |
Why?
|
| Gastroscopy | 1 | 2020 | 45 | 0.710 |
Why?
|
| Stomach Neoplasms | 1 | 2020 | 64 | 0.700 |
Why?
|
| United States | 43 | 2022 | 7367 | 0.690 |
Why?
|
| Healthcare Disparities | 3 | 2020 | 378 | 0.680 |
Why?
|
| Aged, 80 and over | 35 | 2021 | 4848 | 0.660 |
Why?
|
| Estrogen Replacement Therapy | 6 | 2016 | 38 | 0.650 |
Why?
|
| Risk Assessment | 37 | 2019 | 2007 | 0.650 |
Why?
|
| Alcohol Drinking | 11 | 2016 | 805 | 0.620 |
Why?
|
| Mass Screening | 6 | 2020 | 843 | 0.600 |
Why?
|
| Adenocarcinoma | 6 | 2018 | 475 | 0.600 |
Why?
|
| Dietary Supplements | 10 | 2019 | 332 | 0.590 |
Why?
|
| Polymorphism, Genetic | 7 | 2015 | 301 | 0.590 |
Why?
|
| Neoplasms, Radiation-Induced | 6 | 2019 | 79 | 0.570 |
Why?
|
| Incidence | 31 | 2018 | 1603 | 0.560 |
Why?
|
| Diet | 10 | 2014 | 514 | 0.560 |
Why?
|
| Odds Ratio | 23 | 2019 | 880 | 0.560 |
Why?
|
| Adenosine Triphosphatases | 11 | 2015 | 83 | 0.550 |
Why?
|
| Body Mass Index | 10 | 2015 | 867 | 0.540 |
Why?
|
| Logistic Models | 22 | 2017 | 1420 | 0.540 |
Why?
|
| Neoplasm Recurrence, Local | 9 | 2017 | 446 | 0.530 |
Why?
|
| BRCA2 Protein | 7 | 2017 | 18 | 0.530 |
Why?
|
| Family Health | 9 | 2020 | 83 | 0.510 |
Why?
|
| Colonoscopy | 15 | 2014 | 156 | 0.510 |
Why?
|
| Young Adult | 34 | 2021 | 5717 | 0.510 |
Why?
|
| Australia | 17 | 2018 | 235 | 0.490 |
Why?
|
| Promoter Regions, Genetic | 4 | 2015 | 615 | 0.490 |
Why?
|
| Biomarkers, Tumor | 8 | 2016 | 508 | 0.480 |
Why?
|
| Colonic Polyps | 10 | 2013 | 63 | 0.480 |
Why?
|
| Colon | 5 | 2021 | 168 | 0.480 |
Why?
|
| Anticarcinogenic Agents | 6 | 2015 | 52 | 0.460 |
Why?
|
| DNA, Neoplasm | 8 | 2013 | 95 | 0.450 |
Why?
|
| Sigmoidoscopy | 3 | 2011 | 38 | 0.450 |
Why?
|
| Proto-Oncogene Proteins B-raf | 7 | 2013 | 25 | 0.440 |
Why?
|
| Contraceptives, Oral | 3 | 2009 | 28 | 0.440 |
Why?
|
| BRCA1 Protein | 6 | 2017 | 30 | 0.440 |
Why?
|
| Penetrance | 5 | 2019 | 17 | 0.430 |
Why?
|
| Canada | 15 | 2018 | 267 | 0.430 |
Why?
|
| Gene Frequency | 13 | 2017 | 207 | 0.420 |
Why?
|
| Risk | 17 | 2015 | 563 | 0.410 |
Why?
|
| Family | 12 | 2015 | 293 | 0.410 |
Why?
|
| Receptors, Calcitriol | 2 | 2010 | 49 | 0.410 |
Why?
|
| Insurance, Health | 3 | 2018 | 201 | 0.400 |
Why?
|
| DNA Mutational Analysis | 13 | 2015 | 159 | 0.400 |
Why?
|
| SEER Program | 9 | 2020 | 153 | 0.390 |
Why?
|
| Meat | 6 | 2014 | 34 | 0.380 |
Why?
|
| Prognosis | 17 | 2018 | 2093 | 0.380 |
Why?
|
| Follow-Up Studies | 23 | 2019 | 3259 | 0.380 |
Why?
|
| Genetic Loci | 4 | 2015 | 59 | 0.370 |
Why?
|
| Proportional Hazards Models | 15 | 2019 | 792 | 0.370 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2011 | 65 | 0.370 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2011 | 62 | 0.360 |
Why?
|
| Cohort Studies | 20 | 2020 | 2358 | 0.350 |
Why?
|
| Proto-Oncogene Proteins | 6 | 2013 | 411 | 0.350 |
Why?
|
| Gene-Environment Interaction | 6 | 2016 | 31 | 0.350 |
Why?
|
| Neoplasm Staging | 9 | 2020 | 800 | 0.350 |
Why?
|
| Mendelian Randomization Analysis | 3 | 2020 | 10 | 0.350 |
Why?
|
| Tumor Suppressor Proteins | 6 | 2019 | 194 | 0.340 |
Why?
|
| Vitamin D-Binding Protein | 1 | 2010 | 58 | 0.340 |
Why?
|
| Sequence Analysis, DNA | 4 | 2012 | 208 | 0.340 |
Why?
|
| Antioxidants | 4 | 2009 | 304 | 0.330 |
Why?
|
| Age Factors | 13 | 2020 | 1864 | 0.330 |
Why?
|
| Insulin | 1 | 2012 | 619 | 0.330 |
Why?
|
| Radiotherapy | 4 | 2019 | 86 | 0.320 |
Why?
|
| Receptors, Estrogen | 4 | 2017 | 142 | 0.320 |
Why?
|
| Genetic Testing | 5 | 2012 | 159 | 0.320 |
Why?
|
| Lung Neoplasms | 5 | 2018 | 1173 | 0.320 |
Why?
|
| ras Proteins | 4 | 2013 | 102 | 0.310 |
Why?
|
| Receptors, Progesterone | 3 | 2017 | 57 | 0.310 |
Why?
|
| Environmental Exposure | 4 | 2017 | 269 | 0.300 |
Why?
|
| California | 8 | 2018 | 99 | 0.300 |
Why?
|
| Alleles | 11 | 2021 | 386 | 0.290 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 1 | 2006 | 3 | 0.290 |
Why?
|
| Quantitative Trait Loci | 3 | 2017 | 35 | 0.280 |
Why?
|
| Carcinoma in Situ | 1 | 2006 | 47 | 0.270 |
Why?
|
| Chromosome Mapping | 4 | 2016 | 188 | 0.270 |
Why?
|
| Surveys and Questionnaires | 16 | 2016 | 2800 | 0.270 |
Why?
|
| Postmenopause | 3 | 2012 | 93 | 0.270 |
Why?
|
| New Zealand | 9 | 2018 | 28 | 0.270 |
Why?
|
| Prospective Studies | 15 | 2020 | 3705 | 0.270 |
Why?
|
| Phenotype | 13 | 2015 | 947 | 0.260 |
Why?
|
| Genes, ras | 1 | 2006 | 46 | 0.260 |
Why?
|
| Lipid Peroxidation | 1 | 2005 | 94 | 0.260 |
Why?
|
| Dietary Fats, Unsaturated | 1 | 2005 | 8 | 0.250 |
Why?
|
| Signal Transduction | 3 | 2018 | 2689 | 0.250 |
Why?
|
| Genetic Markers | 6 | 2015 | 144 | 0.250 |
Why?
|
| Membrane Transport Proteins | 3 | 2016 | 81 | 0.250 |
Why?
|
| National Cancer Institute (U.S.) | 2 | 2022 | 35 | 0.240 |
Why?
|
| Obesity | 4 | 2017 | 1076 | 0.240 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2016 | 756 | 0.230 |
Why?
|
| Early Detection of Cancer | 2 | 2020 | 454 | 0.230 |
Why?
|
| Calcium, Dietary | 3 | 2010 | 35 | 0.220 |
Why?
|
| Estrogens | 2 | 2016 | 173 | 0.220 |
Why?
|
| Polymerase Chain Reaction | 5 | 2013 | 492 | 0.220 |
Why?
|
| Antigens, Neoplasm | 2 | 2015 | 132 | 0.220 |
Why?
|
| Confidence Intervals | 9 | 2011 | 242 | 0.210 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2015 | 231 | 0.210 |
Why?
|
| Genomics | 4 | 2017 | 168 | 0.210 |
Why?
|
| Social Class | 3 | 2018 | 127 | 0.210 |
Why?
|
| Multivariate Analysis | 11 | 2017 | 1046 | 0.210 |
Why?
|
| Cell Adhesion Molecules | 2 | 2015 | 199 | 0.210 |
Why?
|
| Brassica | 1 | 2002 | 13 | 0.200 |
Why?
|
| Poverty | 2 | 2020 | 219 | 0.200 |
Why?
|
| Environment | 2 | 2013 | 115 | 0.200 |
Why?
|
| Menopause | 5 | 2015 | 47 | 0.190 |
Why?
|
| Genetic Heterogeneity | 1 | 2021 | 11 | 0.190 |
Why?
|
| Reproductive History | 3 | 2012 | 8 | 0.190 |
Why?
|
| Glutathione Transferase | 1 | 2002 | 166 | 0.190 |
Why?
|
| Prostatic Neoplasms | 4 | 2017 | 778 | 0.190 |
Why?
|
| Medicare | 2 | 2020 | 319 | 0.180 |
Why?
|
| Reduced Folate Carrier Protein | 2 | 2011 | 6 | 0.180 |
Why?
|
| Bilirubin | 1 | 2020 | 51 | 0.180 |
Why?
|
| Computational Biology | 4 | 2016 | 190 | 0.180 |
Why?
|
| Stomach | 1 | 2020 | 80 | 0.180 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 772 | 0.180 |
Why?
|
| Carcinogens | 2 | 2011 | 86 | 0.180 |
Why?
|
| Neoplasm Proteins | 3 | 2015 | 307 | 0.180 |
Why?
|
| Epigenomics | 2 | 2017 | 29 | 0.180 |
Why?
|
| Insurance Coverage | 2 | 2018 | 99 | 0.170 |
Why?
|
| Population Surveillance | 6 | 2018 | 285 | 0.170 |
Why?
|
| Adolescent | 14 | 2020 | 8912 | 0.170 |
Why?
|
| Physicians, Primary Care | 1 | 2020 | 46 | 0.170 |
Why?
|
| Thymidylate Synthase | 2 | 2013 | 42 | 0.170 |
Why?
|
| Gene Expression | 2 | 2020 | 770 | 0.170 |
Why?
|
| Retrospective Studies | 10 | 2020 | 7277 | 0.170 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2020 | 47 | 0.170 |
Why?
|
| Cell Cycle Proteins | 4 | 2010 | 230 | 0.170 |
Why?
|
| Gene Deletion | 4 | 2013 | 235 | 0.170 |
Why?
|
| Chromosomes, Human, Pair 9 | 2 | 2010 | 23 | 0.170 |
Why?
|
| Calcium | 3 | 2016 | 929 | 0.170 |
Why?
|
| Age of Onset | 5 | 2021 | 188 | 0.160 |
Why?
|
| X-ray Repair Cross Complementing Protein 1 | 3 | 2010 | 7 | 0.160 |
Why?
|
| Microsatellite Repeats | 7 | 2015 | 40 | 0.160 |
Why?
|
| Metabolomics | 1 | 2018 | 28 | 0.150 |
Why?
|
| Iowa | 6 | 2013 | 33 | 0.150 |
Why?
|
| Epigenesis, Genetic | 4 | 2013 | 163 | 0.150 |
Why?
|
| Homocysteine | 2 | 2019 | 28 | 0.150 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2017 | 43 | 0.150 |
Why?
|
| Referral and Consultation | 1 | 2020 | 383 | 0.150 |
Why?
|
| Carcinogenesis | 2 | 2019 | 124 | 0.150 |
Why?
|
| Contraceptives, Oral, Hormonal | 2 | 2015 | 8 | 0.150 |
Why?
|
| Transcriptome | 2 | 2016 | 164 | 0.150 |
Why?
|
| Genetic Linkage | 3 | 2012 | 90 | 0.150 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2013 | 931 | 0.140 |
Why?
|
| Cancer Care Facilities | 1 | 2017 | 32 | 0.140 |
Why?
|
| Mortality | 1 | 2018 | 163 | 0.140 |
Why?
|
| Parity | 3 | 2012 | 71 | 0.140 |
Why?
|
| Multifactorial Inheritance | 1 | 2016 | 10 | 0.140 |
Why?
|
| Chromatography, High Pressure Liquid | 5 | 2012 | 381 | 0.140 |
Why?
|
| Life Style | 5 | 2012 | 338 | 0.140 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2017 | 59 | 0.140 |
Why?
|
| Exercise Therapy | 1 | 2018 | 183 | 0.140 |
Why?
|
| Vitamin B 12 | 3 | 2012 | 21 | 0.140 |
Why?
|
| Denmark | 7 | 2010 | 24 | 0.140 |
Why?
|
| Disease Management | 1 | 2018 | 248 | 0.140 |
Why?
|
| Weight Reduction Programs | 1 | 2017 | 67 | 0.130 |
Why?
|
| Time Factors | 8 | 2019 | 4655 | 0.130 |
Why?
|
| Vitamin D3 24-Hydroxylase | 1 | 2016 | 24 | 0.130 |
Why?
|
| Rectum | 2 | 2019 | 62 | 0.130 |
Why?
|
| Sex Factors | 7 | 2015 | 1266 | 0.130 |
Why?
|
| Progestins | 1 | 2016 | 19 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2015 | 16 | 0.130 |
Why?
|
| Data Mining | 1 | 2016 | 45 | 0.130 |
Why?
|
| Thyroid Neoplasms | 1 | 2016 | 68 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2010 | 468 | 0.130 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2015 | 1 | 0.130 |
Why?
|
| Skin Neoplasms | 2 | 2017 | 375 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 8 | 3 | 2013 | 54 | 0.130 |
Why?
|
| Ibuprofen | 1 | 2015 | 30 | 0.130 |
Why?
|
| Health Services Accessibility | 2 | 2017 | 581 | 0.130 |
Why?
|
| DNA | 3 | 2013 | 597 | 0.130 |
Why?
|
| Mutation, Missense | 3 | 2011 | 112 | 0.130 |
Why?
|
| Vitamins | 1 | 2016 | 134 | 0.130 |
Why?
|
| Sensitivity and Specificity | 7 | 2020 | 1753 | 0.130 |
Why?
|
| Body Height | 1 | 2015 | 67 | 0.130 |
Why?
|
| Crohn Disease | 1 | 2015 | 38 | 0.130 |
Why?
|
| Estrogen Receptor beta | 1 | 2015 | 19 | 0.120 |
Why?
|
| Hormone Replacement Therapy | 1 | 2015 | 20 | 0.120 |
Why?
|
| Age Distribution | 5 | 2021 | 320 | 0.120 |
Why?
|
| Colitis, Ulcerative | 1 | 2015 | 53 | 0.120 |
Why?
|
| Carcinoma, Large Cell | 1 | 2014 | 6 | 0.120 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2014 | 17 | 0.120 |
Why?
|
| Homeodomain Proteins | 1 | 2015 | 157 | 0.120 |
Why?
|
| Bioprosthesis | 1 | 2015 | 101 | 0.120 |
Why?
|
| Qb-SNARE Proteins | 1 | 2014 | 2 | 0.120 |
Why?
|
| Weight Loss | 1 | 2017 | 319 | 0.120 |
Why?
|
| Breast | 2 | 2013 | 137 | 0.120 |
Why?
|
| Calcium Compounds | 2 | 2004 | 3 | 0.120 |
Why?
|
| Antineoplastic Agents | 2 | 2013 | 1070 | 0.120 |
Why?
|
| Ovarian Neoplasms | 1 | 2016 | 267 | 0.120 |
Why?
|
| Phosphofructokinase-1, Muscle Type | 1 | 2014 | 1 | 0.120 |
Why?
|
| Prevalence | 5 | 2016 | 1619 | 0.120 |
Why?
|
| Carrier Proteins | 4 | 2013 | 597 | 0.120 |
Why?
|
| Heart Valve Prosthesis | 1 | 2015 | 222 | 0.120 |
Why?
|
| Sequence Deletion | 2 | 2010 | 89 | 0.110 |
Why?
|
| Genetic Pleiotropy | 1 | 2013 | 10 | 0.110 |
Why?
|
| Melanoma | 1 | 2017 | 335 | 0.110 |
Why?
|
| Double-Blind Method | 8 | 2010 | 1738 | 0.110 |
Why?
|
| 3' Untranslated Regions | 1 | 2013 | 56 | 0.110 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 504 | 0.110 |
Why?
|
| Sex Distribution | 5 | 2015 | 274 | 0.110 |
Why?
|
| Smad7 Protein | 1 | 2013 | 11 | 0.110 |
Why?
|
| Leukocytes | 1 | 2013 | 99 | 0.110 |
Why?
|
| Exome | 1 | 2013 | 20 | 0.110 |
Why?
|
| S-Adenosylmethionine | 1 | 2013 | 9 | 0.110 |
Why?
|
| 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase | 1 | 2013 | 2 | 0.110 |
Why?
|
| Telomere | 1 | 2013 | 59 | 0.110 |
Why?
|
| Ferredoxin-NADP Reductase | 1 | 2013 | 3 | 0.110 |
Why?
|
| Cyclin D2 | 1 | 2012 | 5 | 0.110 |
Why?
|
| Survival Analysis | 4 | 2019 | 714 | 0.110 |
Why?
|
| Pedigree | 4 | 2016 | 159 | 0.110 |
Why?
|
| Meta-Analysis as Topic | 1 | 2013 | 57 | 0.110 |
Why?
|
| Pharmacogenetics | 1 | 2013 | 47 | 0.110 |
Why?
|
| DNA Copy Number Variations | 1 | 2013 | 27 | 0.110 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2013 | 68 | 0.110 |
Why?
|
| Digestive System Neoplasms | 1 | 2012 | 13 | 0.110 |
Why?
|
| Urogenital Neoplasms | 1 | 2012 | 9 | 0.110 |
Why?
|
| Radiography, Thoracic | 1 | 2013 | 99 | 0.110 |
Why?
|
| Carrier State | 1 | 2013 | 39 | 0.110 |
Why?
|
| Vitamin D | 2 | 2010 | 516 | 0.110 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2015 | 300 | 0.100 |
Why?
|
| Gene Expression Profiling | 3 | 2016 | 498 | 0.100 |
Why?
|
| Population Dynamics | 1 | 2012 | 30 | 0.100 |
Why?
|
| Proteins | 1 | 2015 | 474 | 0.100 |
Why?
|
| Epithelial Cell Adhesion Molecule | 3 | 2019 | 12 | 0.100 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 4 | 2013 | 78 | 0.100 |
Why?
|
| Micronutrients | 1 | 2012 | 31 | 0.100 |
Why?
|
| Lipocalins | 1 | 2011 | 7 | 0.100 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2011 | 10 | 0.100 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2012 | 47 | 0.100 |
Why?
|
| Europe | 3 | 2020 | 196 | 0.100 |
Why?
|
| Research Design | 5 | 2009 | 729 | 0.100 |
Why?
|
| Medical History Taking | 3 | 2019 | 94 | 0.100 |
Why?
|
| Tamoxifen | 2 | 2010 | 62 | 0.100 |
Why?
|
| Dietary Fiber | 2 | 2014 | 37 | 0.100 |
Why?
|
| Amino Acid Substitution | 1 | 2011 | 137 | 0.100 |
Why?
|
| Immunohistochemistry | 5 | 2015 | 1174 | 0.090 |
Why?
|
| Genomic Imprinting | 1 | 2010 | 10 | 0.090 |
Why?
|
| Receptors, Calcium-Sensing | 1 | 2010 | 10 | 0.090 |
Why?
|
| Receptor, ErbB-2 | 1 | 2011 | 129 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2013 | 536 | 0.090 |
Why?
|
| Retinoid X Receptors | 1 | 2010 | 26 | 0.090 |
Why?
|
| Bayes Theorem | 3 | 2021 | 307 | 0.090 |
Why?
|
| Body Weight | 1 | 2012 | 554 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2019 | 1085 | 0.090 |
Why?
|
| gamma-Glutamyl Hydrolase | 1 | 2009 | 6 | 0.090 |
Why?
|
| Folate Receptor 1 | 1 | 2009 | 2 | 0.090 |
Why?
|
| Folate Receptors, GPI-Anchored | 1 | 2009 | 6 | 0.090 |
Why?
|
| Peptide Synthases | 1 | 2009 | 13 | 0.090 |
Why?
|
| Feeding Behavior | 1 | 2012 | 224 | 0.090 |
Why?
|
| Models, Genetic | 4 | 2015 | 161 | 0.090 |
Why?
|
| Rectal Diseases | 1 | 2009 | 13 | 0.080 |
Why?
|
| Likelihood Functions | 4 | 2012 | 106 | 0.080 |
Why?
|
| Long Interspersed Nucleotide Elements | 1 | 2009 | 4 | 0.080 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2014 | 629 | 0.080 |
Why?
|
| Linear Models | 5 | 2009 | 521 | 0.080 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 1 | 2009 | 37 | 0.080 |
Why?
|
| Radiation Injuries | 1 | 2010 | 97 | 0.080 |
Why?
|
| Vitamin B Complex | 1 | 2009 | 26 | 0.080 |
Why?
|
| Reproducibility of Results | 5 | 2018 | 2077 | 0.080 |
Why?
|
| Chromatography, Liquid | 2 | 2019 | 120 | 0.080 |
Why?
|
| Receptors, Cell Surface | 1 | 2009 | 248 | 0.080 |
Why?
|
| Base Pair Mismatch | 2 | 2005 | 12 | 0.080 |
Why?
|
| Overweight | 1 | 2010 | 186 | 0.080 |
Why?
|
| Adenomatous Polyposis Coli | 2 | 2006 | 26 | 0.080 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2007 | 6 | 0.080 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2008 | 52 | 0.070 |
Why?
|
| Health Promotion | 1 | 2011 | 407 | 0.070 |
Why?
|
| Menarche | 3 | 2015 | 18 | 0.070 |
Why?
|
| Ovary | 1 | 2007 | 99 | 0.070 |
Why?
|
| History, 21st Century | 2 | 2018 | 127 | 0.070 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2007 | 99 | 0.070 |
Why?
|
| Inflammation | 1 | 2013 | 1030 | 0.070 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 4 | 2010 | 12 | 0.070 |
Why?
|
| Los Angeles | 1 | 2006 | 30 | 0.070 |
Why?
|
| Ornithine Decarboxylase | 1 | 2006 | 17 | 0.070 |
Why?
|
| Adenomatous Polyps | 1 | 2006 | 18 | 0.070 |
Why?
|
| Medically Uninsured | 2 | 2018 | 99 | 0.070 |
Why?
|
| History, 20th Century | 2 | 2018 | 248 | 0.070 |
Why?
|
| Neoplasm Grading | 2 | 2017 | 111 | 0.070 |
Why?
|
| Models, Biological | 1 | 2011 | 981 | 0.070 |
Why?
|
| Predictive Value of Tests | 4 | 2015 | 1465 | 0.070 |
Why?
|
| Gastrointestinal Agents | 1 | 2006 | 51 | 0.070 |
Why?
|
| Survival Rate | 3 | 2015 | 1056 | 0.070 |
Why?
|
| Vitamin B 6 | 3 | 2012 | 4 | 0.070 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2010 | 468 | 0.070 |
Why?
|
| Gastroenterology | 1 | 2007 | 98 | 0.070 |
Why?
|
| Residence Characteristics | 2 | 2018 | 252 | 0.070 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2005 | 24 | 0.060 |
Why?
|
| Dietary Fats | 1 | 2005 | 103 | 0.060 |
Why?
|
| Radiation Dosage | 3 | 2013 | 419 | 0.060 |
Why?
|
| Chromosomal Instability | 1 | 2005 | 14 | 0.060 |
Why?
|
| Gene Conversion | 1 | 2005 | 4 | 0.060 |
Why?
|
| Tumor Burden | 2 | 2017 | 132 | 0.060 |
Why?
|
| Jews | 1 | 2004 | 7 | 0.060 |
Why?
|
| Mutagens | 1 | 2004 | 18 | 0.060 |
Why?
|
| Selection Bias | 1 | 2004 | 23 | 0.060 |
Why?
|
| Placebos | 3 | 2010 | 195 | 0.060 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2005 | 73 | 0.060 |
Why?
|
| Heredity | 2 | 2015 | 9 | 0.060 |
Why?
|
| Genome, Human | 2 | 2017 | 62 | 0.060 |
Why?
|
| Genetic Association Studies | 2 | 2017 | 103 | 0.060 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2006 | 235 | 0.060 |
Why?
|
| Breast Feeding | 3 | 2012 | 159 | 0.060 |
Why?
|
| Hawaii | 2 | 2014 | 24 | 0.060 |
Why?
|
| Cocarcinogenesis | 1 | 2004 | 4 | 0.060 |
Why?
|
| Reference Values | 3 | 2011 | 579 | 0.060 |
Why?
|
| Victoria | 2 | 2016 | 8 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 15 | 2 | 2015 | 9 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 12 | 2 | 2015 | 16 | 0.060 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2004 | 61 | 0.060 |
Why?
|
| Treatment Outcome | 7 | 2010 | 7029 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 4 | 2 | 2014 | 15 | 0.060 |
Why?
|
| beta Carotene | 1 | 2003 | 16 | 0.060 |
Why?
|
| Poisson Distribution | 3 | 2008 | 85 | 0.060 |
Why?
|
| Animals | 6 | 2012 | 20881 | 0.050 |
Why?
|
| Chi-Square Distribution | 3 | 2008 | 546 | 0.050 |
Why?
|
| Paraffin Embedding | 1 | 2002 | 47 | 0.050 |
Why?
|
| Diet Records | 1 | 2002 | 14 | 0.050 |
Why?
|
| Regression Analysis | 2 | 2014 | 737 | 0.050 |
Why?
|
| Area Under Curve | 2 | 2012 | 238 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 3 | 2009 | 186 | 0.050 |
Why?
|
| Cell Differentiation | 1 | 2005 | 1034 | 0.050 |
Why?
|
| Eating | 1 | 2002 | 119 | 0.050 |
Why?
|
| Colon, Transverse | 1 | 2021 | 2 | 0.050 |
Why?
|
| Colon, Ascending | 1 | 2021 | 3 | 0.050 |
Why?
|
| Colon, Descending | 1 | 2021 | 3 | 0.050 |
Why?
|
| Sialyltransferases | 1 | 2021 | 7 | 0.050 |
Why?
|
| Colon, Sigmoid | 1 | 2021 | 13 | 0.050 |
Why?
|
| Cecum | 1 | 2021 | 39 | 0.050 |
Why?
|
| Salpingo-oophorectomy | 1 | 2020 | 2 | 0.050 |
Why?
|
| Biomarkers | 2 | 2019 | 1593 | 0.050 |
Why?
|
| Child | 3 | 2018 | 6405 | 0.050 |
Why?
|
| Haplotypes | 2 | 2011 | 174 | 0.050 |
Why?
|
| Hysterectomy | 1 | 2020 | 64 | 0.050 |
Why?
|
| Poultry | 2 | 2011 | 14 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2018 | 2279 | 0.040 |
Why?
|
| Pregnancy | 3 | 2012 | 2334 | 0.040 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2010 | 100 | 0.040 |
Why?
|
| Interviews as Topic | 2 | 2014 | 392 | 0.040 |
Why?
|
| Biological Variation, Population | 1 | 2019 | 8 | 0.040 |
Why?
|
| Infant | 2 | 2018 | 2891 | 0.040 |
Why?
|
| DNA Modification Methylases | 1 | 2019 | 24 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2019 | 52 | 0.040 |
Why?
|
| Women's Health | 2 | 2012 | 148 | 0.040 |
Why?
|
| Child, Preschool | 2 | 2018 | 3187 | 0.040 |
Why?
|
| Triglycerides | 1 | 2019 | 184 | 0.040 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2019 | 139 | 0.040 |
Why?
|
| Apoptosis | 1 | 2005 | 1641 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2010 | 129 | 0.040 |
Why?
|
| Metabolome | 1 | 2018 | 15 | 0.040 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2018 | 59 | 0.040 |
Why?
|
| Cholesterol | 1 | 2019 | 331 | 0.040 |
Why?
|
| Models, Statistical | 2 | 2012 | 448 | 0.040 |
Why?
|
| Cyclooxygenase 2 | 2 | 2011 | 160 | 0.040 |
Why?
|
| RNA, Long Noncoding | 1 | 2018 | 54 | 0.040 |
Why?
|
| Cancer Survivors | 1 | 2020 | 146 | 0.040 |
Why?
|
| Phantoms, Imaging | 2 | 2012 | 189 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2017 | 11 | 0.040 |
Why?
|
| Genetic Carrier Screening | 2 | 2010 | 25 | 0.040 |
Why?
|
| Sex Characteristics | 1 | 2019 | 295 | 0.040 |
Why?
|
| Cause of Death | 1 | 2018 | 241 | 0.040 |
Why?
|
| Geography | 1 | 2017 | 80 | 0.040 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2017 | 29 | 0.040 |
Why?
|
| Educational Status | 1 | 2017 | 273 | 0.030 |
Why?
|
| Income | 1 | 2017 | 167 | 0.030 |
Why?
|
| Carcinoma, Papillary | 1 | 2016 | 35 | 0.030 |
Why?
|
| Caco-2 Cells | 1 | 2016 | 37 | 0.030 |
Why?
|
| Thymus Gland | 1 | 2016 | 97 | 0.030 |
Why?
|
| A549 Cells | 1 | 2016 | 50 | 0.030 |
Why?
|
| Lymphoma | 1 | 2017 | 116 | 0.030 |
Why?
|
| HCT116 Cells | 1 | 2016 | 63 | 0.030 |
Why?
|
| Hep G2 Cells | 1 | 2016 | 68 | 0.030 |
Why?
|
| Leukemia | 1 | 2017 | 117 | 0.030 |
Why?
|
| Ontario | 1 | 2016 | 24 | 0.030 |
Why?
|
| Datasets as Topic | 1 | 2016 | 53 | 0.030 |
Why?
|
| Bone Neoplasms | 1 | 2017 | 100 | 0.030 |
Why?
|
| Radiotherapy Dosage | 2 | 2008 | 125 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2017 | 186 | 0.030 |
Why?
|
| Probability | 2 | 2007 | 245 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2016 | 219 | 0.030 |
Why?
|
| Sweden | 1 | 2015 | 21 | 0.030 |
Why?
|
| Medicaid | 1 | 2018 | 302 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2016 | 306 | 0.030 |
Why?
|
| Maternal Age | 1 | 2015 | 70 | 0.030 |
Why?
|
| Warfarin | 1 | 2015 | 93 | 0.030 |
Why?
|
| Observer Variation | 2 | 2009 | 330 | 0.030 |
Why?
|
| Asia | 1 | 2014 | 59 | 0.030 |
Why?
|
| Repressor Proteins | 1 | 2015 | 183 | 0.030 |
Why?
|
| Japan | 1 | 2014 | 68 | 0.030 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2015 | 216 | 0.030 |
Why?
|
| Bias | 1 | 2015 | 148 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2017 | 955 | 0.030 |
Why?
|
| Health Status Disparities | 1 | 2017 | 326 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2017 | 622 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 649 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2018 | 1342 | 0.030 |
Why?
|
| North America | 1 | 2014 | 112 | 0.030 |
Why?
|
| Membrane Proteins | 2 | 2010 | 617 | 0.030 |
Why?
|
| Epidemiologic Studies | 1 | 2013 | 33 | 0.030 |
Why?
|
| Fruit | 1 | 2014 | 86 | 0.030 |
Why?
|
| Vegetables | 1 | 2014 | 76 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2013 | 19 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2013 | 55 | 0.030 |
Why?
|
| Methyltransferases | 1 | 2013 | 19 | 0.030 |
Why?
|
| Molecular Epidemiology | 1 | 2013 | 16 | 0.030 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2013 | 62 | 0.030 |
Why?
|
| Allelic Imbalance | 1 | 2013 | 3 | 0.030 |
Why?
|
| Urologic Neoplasms | 1 | 2013 | 14 | 0.030 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2013 | 51 | 0.030 |
Why?
|
| Finland | 1 | 2012 | 13 | 0.030 |
Why?
|
| T-Box Domain Proteins | 1 | 2012 | 29 | 0.030 |
Why?
|
| Survivors | 1 | 2015 | 256 | 0.030 |
Why?
|
| Laminin | 1 | 2012 | 62 | 0.030 |
Why?
|
| Ohio | 1 | 2012 | 64 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 1745 | 0.030 |
Why?
|
| Immunity, Innate | 1 | 2013 | 156 | 0.030 |
Why?
|
| Lod Score | 1 | 2012 | 14 | 0.030 |
Why?
|
| Latin America | 1 | 2012 | 19 | 0.030 |
Why?
|
| Alternative Splicing | 1 | 2012 | 93 | 0.030 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2012 | 16 | 0.030 |
Why?
|
| Genes, Neoplasm | 1 | 2012 | 18 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 2 | 2005 | 329 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2018 | 2455 | 0.030 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2011 | 19 | 0.030 |
Why?
|
| Acid Anhydride Hydrolases | 1 | 2011 | 13 | 0.020 |
Why?
|
| Biopsy, Needle | 2 | 2002 | 191 | 0.020 |
Why?
|
| Cytochrome P-450 CYP1B1 | 1 | 2011 | 5 | 0.020 |
Why?
|
| Cytochrome P-450 CYP1A2 | 1 | 2011 | 4 | 0.020 |
Why?
|
| Arylamine N-Acetyltransferase | 1 | 2011 | 11 | 0.020 |
Why?
|
| Cytochrome P-450 CYP2E1 | 1 | 2011 | 11 | 0.020 |
Why?
|
| Epoxide Hydrolases | 1 | 2011 | 8 | 0.020 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2011 | 11 | 0.020 |
Why?
|
| Hospitalization | 1 | 2017 | 978 | 0.020 |
Why?
|
| Enzyme Stability | 1 | 2011 | 30 | 0.020 |
Why?
|
| Cooking | 1 | 2011 | 19 | 0.020 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2011 | 24 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 320 | 0.020 |
Why?
|
| Heterocyclic Compounds | 1 | 2011 | 24 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2015 | 706 | 0.020 |
Why?
|
| Transgenes | 1 | 2011 | 92 | 0.020 |
Why?
|
| Morbidity | 1 | 2011 | 130 | 0.020 |
Why?
|
| Gene Knockout Techniques | 1 | 2011 | 61 | 0.020 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2011 | 53 | 0.020 |
Why?
|
| Ligase Chain Reaction | 1 | 2010 | 1 | 0.020 |
Why?
|
| DNA-(Apurinic or Apyrimidinic Site) Lyase | 1 | 2010 | 7 | 0.020 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2010 | 39 | 0.020 |
Why?
|
| ROC Curve | 1 | 2012 | 392 | 0.020 |
Why?
|
| Gene Duplication | 1 | 2010 | 12 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 2010 | 83 | 0.020 |
Why?
|
| Amines | 1 | 2011 | 98 | 0.020 |
Why?
|
| Fathers | 1 | 2010 | 16 | 0.020 |
Why?
|
| Colectomy | 1 | 2010 | 64 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2010 | 91 | 0.020 |
Why?
|
| Nutrition Surveys | 1 | 2012 | 208 | 0.020 |
Why?
|
| Breast Neoplasms, Male | 1 | 2010 | 12 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2011 | 362 | 0.020 |
Why?
|
| Ethanol | 1 | 2016 | 893 | 0.020 |
Why?
|
| Isoenzymes | 1 | 2011 | 308 | 0.020 |
Why?
|
| Estrogen Receptor alpha | 1 | 2010 | 65 | 0.020 |
Why?
|
| Mutagenesis, Insertional | 1 | 2009 | 24 | 0.020 |
Why?
|
| Indians, North American | 1 | 2010 | 64 | 0.020 |
Why?
|
| Quality Assurance, Health Care | 1 | 2011 | 177 | 0.020 |
Why?
|
| Temperature | 1 | 2011 | 341 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2010 | 146 | 0.020 |
Why?
|
| International Cooperation | 1 | 2010 | 88 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 2010 | 219 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2011 | 546 | 0.020 |
Why?
|
| Weight Gain | 1 | 2010 | 135 | 0.020 |
Why?
|
| Precancerous Conditions | 1 | 2009 | 74 | 0.020 |
Why?
|
| DNA Damage | 1 | 2010 | 190 | 0.020 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2009 | 73 | 0.020 |
Why?
|
| Mothers | 1 | 2010 | 172 | 0.020 |
Why?
|
| Riboflavin | 1 | 2008 | 15 | 0.020 |
Why?
|
| Siblings | 1 | 2008 | 34 | 0.020 |
Why?
|
| Relative Biological Effectiveness | 1 | 2008 | 10 | 0.020 |
Why?
|
| Chemoprevention | 1 | 2008 | 26 | 0.020 |
Why?
|
| Sheep | 1 | 2008 | 128 | 0.020 |
Why?
|
| Body Burden | 1 | 2008 | 27 | 0.020 |
Why?
|
| Hot Temperature | 1 | 2008 | 152 | 0.020 |
Why?
|
| Matched-Pair Analysis | 1 | 2008 | 25 | 0.020 |
Why?
|
| Cattle | 1 | 2008 | 475 | 0.020 |
Why?
|
| Information Systems | 1 | 2007 | 45 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2007 | 129 | 0.020 |
Why?
|
| Methotrexate | 1 | 2007 | 91 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2007 | 125 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2007 | 130 | 0.020 |
Why?
|
| Gravidity | 1 | 2007 | 11 | 0.020 |
Why?
|
| Protein Binding | 1 | 2010 | 1027 | 0.020 |
Why?
|
| Swine | 1 | 2008 | 672 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2007 | 216 | 0.020 |
Why?
|
| Alanine | 1 | 2006 | 38 | 0.020 |
Why?
|
| Health Behavior | 1 | 2010 | 458 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2007 | 231 | 0.020 |
Why?
|
| Glycine | 1 | 2006 | 89 | 0.020 |
Why?
|
| Medical Oncology | 1 | 2007 | 110 | 0.020 |
Why?
|
| Genomic Instability | 1 | 2006 | 41 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2006 | 137 | 0.020 |
Why?
|
| Data Collection | 1 | 2007 | 420 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2007 | 369 | 0.020 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2005 | 14 | 0.020 |
Why?
|
| Cyclooxygenase 1 | 1 | 2005 | 29 | 0.020 |
Why?
|
| Blotting, Southern | 1 | 2005 | 67 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2005 | 260 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2005 | 274 | 0.020 |
Why?
|
| Comorbidity | 1 | 2009 | 1426 | 0.020 |
Why?
|
| Recurrence | 1 | 2006 | 948 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 2003 | 5 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 2004 | 249 | 0.010 |
Why?
|
| Quality Control | 1 | 2003 | 81 | 0.010 |
Why?
|
| Secondary Prevention | 1 | 2003 | 291 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2005 | 1664 | 0.010 |
Why?
|
| Patient Compliance | 1 | 2003 | 402 | 0.010 |
Why?
|
| Mice | 1 | 2011 | 8474 | 0.010 |
Why?
|
| Alcoholism | 1 | 2002 | 1109 | 0.010 |
Why?
|